Results 221 to 230 of about 1,994,731 (278)
Some of the next articles are maybe not open access.
RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse
Histochemistry and Cell Biology, 2002Rheumatoid arthritis (RA) is a systemic disorder characterized by synovial inflammation and subsequent destruction and deformity of synovial joints. The articular lesions start with synovitis, focal erosion of unmineralized cartilage, and then culminate in the destruction of subarticular bone by pannus tissue.
Hiroyuki, Mori +5 more
openaire +3 more sources
RANK Ligand: Effects of Inhibition
Current Oncology Reports, 2010Receptor activator of nuclear factor kappa-light-chain-enhancer of activated B-cells (RANK) and its ligand (RANKL) belong to the tumor necrosis factor (TNF) superfamily. RANK mRNA is expressed widely in bone and bone marrow. It has a significant role in stimulating osteoclast differentiation and maturation, and also in preventing apoptosis.
Saby, George +3 more
openaire +2 more sources
Ranking the role of RANK ligand in apoptosis
Apoptosis, 2004Many members of tumor necrosis factor (TNF) superfamily are characterized by their ability to induce apoptosis once they bind in a homotrimeric manner to their cognate receptors. The receptor activator of nuclear factor-kappaB ligand (RANKL), a member of the TNF superfamily identified seven years ago, was originally described as a factor that induced ...
A C, Bharti, B B, Aggarwal
openaire +2 more sources
Osteoprotegerin and rank ligand expression in prostate cancer
Urology, 2001To investigate the expression of osteoprotegerin (OPG) and RANK ligand (RANKL) in human prostatic tissues. The factors regulating the increased turnover associated with prostate cancer (CaP) bone metastasis are unknown. OPG and RANKL are recently identified regulators of bone resorption and bone remodeling.Tissues from 28 patients with CaP and from 4 ...
J M, Brown +6 more
openaire +2 more sources
Clinical applications of RANK‐ligand inhibition
Internal Medicine Journal, 2009AbstractAn enhanced rate of bone remodelling fuelled by osteoclastogenesis mediates diseases such as osteoporosis, arthritic bone destruction, Paget’s disease and malignancy‐induced bone loss. Thus, the control of osteoclastogenesis is of major clinical importance.
openaire +2 more sources
RANK ligand and osteoprotegerin in myeloma bone disease
Blood, 2003Myeloma bone disease is due to interactions of myeloma cells with the bone marrow microenvironment, and is associated with pathologic fractures, neurologic symptoms and hypercalcemia. Adjacent to myeloma cells, the formation and activation of osteoclasts is increased, which results in enhanced bone resorption.
Orhan, Sezer +4 more
openaire +2 more sources
Bone, 2012
increased fracture risk occur early after therapy is initiated, emphasising the importance of primary prevention of fracture in high-risk individuals. Most currently available guidelines for the management of GIO were developed prior to the release of FRAX® and other risk assessment tools and the approval of newer pharmacological interventions for its ...
openaire +1 more source
increased fracture risk occur early after therapy is initiated, emphasising the importance of primary prevention of fracture in high-risk individuals. Most currently available guidelines for the management of GIO were developed prior to the release of FRAX® and other risk assessment tools and the approval of newer pharmacological interventions for its ...
openaire +1 more source
Expression of RANK‐ligand in prostate cancer cell lines
Scandinavian Journal of Clinical and Laboratory Investigation, 2009The molecular mediators of bone remodelling, receptor activator of nuclear factor-kappaB ligand (RANKL), receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerine (OPG), are believed to be involved in the cellular mechanisms by which tumours metastasize to bone. RANKL is a potent stimulator of osteoclastic bone resorption and is expressed
Hendrik, Penno +4 more
openaire +2 more sources
TNF‐α expression is transcriptionally regulated by RANK ligand
Journal of Cellular Physiology, 2004AbstractTumor necrosis factor (TNF)‐α is known for its osteoclastogenic and resorptive activities. Induction of osteoclastogenesis by receptor activator of NF‐κB ligand (RANKL) is accompanied by increased TNF‐α expression. In the present study we investigated the mechanism by which RANKL induces expression of TNF‐α in osteoclast precursors.
W, Zou +4 more
openaire +2 more sources
Osteoprotegerin, rank and rank ligand
2007The discovery of the osteoprotegerin, receptor activator of nuclear factor-kappa B ligand and receptor activator of nuclear factor-kappa B and identification of their role in osteoclastogenesis provided a major advance in bone biology. receptor activator of nuclear factor-kappa B ligand binds to its receptors on the surface of preosteoclasts and ...
Kurban, Sevil, Mehmetoglu, Idris
openaire +1 more source